Elevated C-reactive protein and monocyte chemoattractant protein-1 in patients with polycystic ovary syndrome

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 157, Issue 1, 2011, Pages 53-56

  Hu, Weihong ^a,b   Qiao, Jie ^a   Yang, Yan ^a   Wang, Lina ^a   Li, Rong ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

C reactive protein; Inflammation; Monocyte chemoattractant protein 1; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; BODY MASS; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN BLOOD LEVEL; MACROPHAGE; MAJOR CLINICAL STUDY; MONOCYTE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

EID: 79958813564     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2011.03.015     Document Type: Article

References (39)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of south eastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82. (Pubitemid 28500937)
2. Guzick DS. Polycystic ovary syndrome. Obstet Gynecol 2004;103:181-93. (Pubitemid 39248484)
3. Conway GS, Agrawal R, Betteridge DJ, et al. Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;37:119-25.
4. Dahlgren E, Janson O, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
5. Talbott E, Guzick D, Clerici A, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821-6.
6. Hendarson CW. PCOS may lead to early onset of atherosclerosis even among thin women. Womens Health Wkly 2000;11:2-3.
7. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein( a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5. (Pubitemid 32433842)
8. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in primary prevention of cardiovascular disease. Circulation 2001;103:1813-8. (Pubitemid 32291421)
9. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4. (Pubitemid 32521959)
10. Dörffel Y, Franz S, Pruss A, et al. Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? Atherosclerosis 2001;157:151-60.
11. Rollins BJ. JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. Cancer Cells 1991;3:517-24.
12. Aiello RJ, Bourassa PA, Lindsey S, et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:1518-25. (Pubitemid 29263023)
13. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 2003;41:834-41. (Pubitemid 36314600)
14. Nelken NA, Coughlin SR, Gordon D, et al. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991;88:1121-7.
15. de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107: 690-5.
16. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-22.
17. Weber C, Schober A, Zernecke A. Chemokines, key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004;24:1997-2008. (Pubitemid 39482421)
18. Martinovic I, Abegunewardene N, Seul M, et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 2005;69:1484-9. (Pubitemid 41743963)
19. Deo R, Khera A, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004;44:1812-8. (Pubitemid 39424080)
20. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-5. (Pubitemid 38619847)
21. González F, Rote NS, Minium J, et al. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009;58:954-62.
22. Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-5. (Pubitemid 32545690)
23. Hu WH, Qiao J, Zhao SY, et al. Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome. Beijing Da Xue Xue Bao 2006;38:487-91.
24. Morin-Papunen L, Rautio K, Ruokonen A, et al. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649-54. (Pubitemid 37357506)
25. Dunaif A. Insulin resistance and polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1998;18:774-800.
26. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165-74. (Pubitemid 19250404)
27. Vrbikova J, Bendlova B, Hill M, et al. Insulin sensitivity and beta-cell function in women with polycystic ovary syndrome. Diabetes Care 2002;25:1217-22. (Pubitemid 41071175)
28. Festa A, D'Agostino Jr R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-7. (Pubitemid 30430551)
29. Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun 2006;344:780-5.
30. Simeoni E, Hoffmann MM, Winkelmann RR, et al. Association between the A- 1518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus. Diabetologia 2004;47: 1574-80. (Pubitemid 39371640)
31. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:7265-70. (Pubitemid 36706427)
32. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 1992;12:1789-97.
33. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-36.
34. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808. (Pubitemid 38063703)
35. Xu HY, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30. (Pubitemid 38063705)
36. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-505.
37. Moran LJ, Noakes M, Clifton PM, et al. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2944-51. (Pubitemid 47236354)
38. Glintborg D, Andersen M, Richelsen B, et al. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1a are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf) 2009;71:652-8.
39. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004;109:2566-71. (Pubitemid 38720558)